Extracellular Vesicle-Based SARS-CoV-2 Vaccine

Messenger ribonucleic acid (RNA) vaccines are mainly used as SARS-CoV-2 vaccines. Despite several issues concerning storage, stability, effective period, and side effects, viral vector vaccines are widely used for the prevention and treatment of various diseases. Recently, viral vector-encapsulated...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuzaka, Yasunari, Yashiro, Ryu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058598/
https://www.ncbi.nlm.nih.gov/pubmed/36992123
http://dx.doi.org/10.3390/vaccines11030539
_version_ 1785016670260035584
author Matsuzaka, Yasunari
Yashiro, Ryu
author_facet Matsuzaka, Yasunari
Yashiro, Ryu
author_sort Matsuzaka, Yasunari
collection PubMed
description Messenger ribonucleic acid (RNA) vaccines are mainly used as SARS-CoV-2 vaccines. Despite several issues concerning storage, stability, effective period, and side effects, viral vector vaccines are widely used for the prevention and treatment of various diseases. Recently, viral vector-encapsulated extracellular vesicles (EVs) have been suggested as useful tools, owing to their safety and ability to escape from neutral antibodies. Herein, we summarize the possible cellular mechanisms underlying EV-based SARS-CoV-2 vaccines.
format Online
Article
Text
id pubmed-10058598
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100585982023-03-30 Extracellular Vesicle-Based SARS-CoV-2 Vaccine Matsuzaka, Yasunari Yashiro, Ryu Vaccines (Basel) Review Messenger ribonucleic acid (RNA) vaccines are mainly used as SARS-CoV-2 vaccines. Despite several issues concerning storage, stability, effective period, and side effects, viral vector vaccines are widely used for the prevention and treatment of various diseases. Recently, viral vector-encapsulated extracellular vesicles (EVs) have been suggested as useful tools, owing to their safety and ability to escape from neutral antibodies. Herein, we summarize the possible cellular mechanisms underlying EV-based SARS-CoV-2 vaccines. MDPI 2023-02-24 /pmc/articles/PMC10058598/ /pubmed/36992123 http://dx.doi.org/10.3390/vaccines11030539 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Matsuzaka, Yasunari
Yashiro, Ryu
Extracellular Vesicle-Based SARS-CoV-2 Vaccine
title Extracellular Vesicle-Based SARS-CoV-2 Vaccine
title_full Extracellular Vesicle-Based SARS-CoV-2 Vaccine
title_fullStr Extracellular Vesicle-Based SARS-CoV-2 Vaccine
title_full_unstemmed Extracellular Vesicle-Based SARS-CoV-2 Vaccine
title_short Extracellular Vesicle-Based SARS-CoV-2 Vaccine
title_sort extracellular vesicle-based sars-cov-2 vaccine
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058598/
https://www.ncbi.nlm.nih.gov/pubmed/36992123
http://dx.doi.org/10.3390/vaccines11030539
work_keys_str_mv AT matsuzakayasunari extracellularvesiclebasedsarscov2vaccine
AT yashiroryu extracellularvesiclebasedsarscov2vaccine

Ejemplares similares